Infusion Systems - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017

Additional Information

GlobalData’s new report, “Infusion Systems - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017” provides key data, information and analysis on the global infusion systems market. The report provides market landscape, competitive landscape and market trends information on the infusion systems market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market’s dynamics. The report also reviews the competitive landscape and technology offerings. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The Global Infusion Systems Market was Valued at $6 billion in 2010

The global infusion systems market was valued at $6 billion in 2010 and is forecast to grow to a value of $8.3 billion by 2017 at a Compound Annual Growth Rate (CAGR) of 4.7%. The market is forecast to grow due to the increase in the chronic pain patient population, advancements in the infusion pump technology with an increased focus on safety and the positive developments in the reimbursement scenario for infusion systems in the US market.

The US and Europe Combine for More than 70% of the Global Infusion Systems Market

In 2010, the US and the European markets together contributed more than 70% towards the global infusion systems market. The majority of sales came from the US, with a contribution of 42% in 2010. The European market for infusion systems contributed 30% to the global revenues in 2010. These two regions are followed by the remaining market geographies such as the Asia Pacific region and South and Central America which contributed 28% to the global revenues.

The main reasons for the significant contribution of the US and Europe towards infusion systems market are significant chronic pain patient population and comparatively better reimbursement scenarios (both private and federal) in these regions when compared to the developing countries such as China and India. Higher affordability is another important factor which enables patients to afford certain types of infusion pumps which are not reimbursed.

Hospira was the Leading Player in the Fragmented Global Infusion Systems Market in 2010

The global infusion systems market is highly fragmented. In 2010, Hospira was the leading player with a 16% market share, due to its strong presence in the US infusion systems market. It was followed by CareFusion with 12% of the global market. Similar to Hospira, CareFusion has a strong presence in the US market as well as enjoying a substantial presence in the European market. Baxter is positioned third in the global infusion systems market with significant presence in Europe.

Increase in the Population of Patients Suffering from Chronic Pain to Drive the Market for Infusion Systems.

The increase in the population of patients suffering from chronic pain is expected to drive the market for infusion systems. This is because chronic pain in patients (suffering from various disorders) is a major medication area for which infusion pump usage is prescribed. Chronic pain affects a significant number of the population as it is not restricted to any specific disease and can also occur as a side effect of a variety of conditions. The prevalence rate for chronic pain is high across the globe. For example, a European survey (including 46,000 people) reported that one in five individuals were suffering from chronic pain. Similarly, an Australian population study of over 17,000 people showed the prevalence of chronic pain in 17.1% of males and 20% of females.

A number of studies point to the strong correlation between chronic pain and increasing age. Hence an increase in the elderly population can result in an increase in the prevalence rate of chronic pain indicating significant growth opportunities for the infusion systems market.

Changes in the US Medicare Reimbursment Policy for Home Based Infusion Therapy can Drive Market Growth

The bill “Medicare Home Infusion Therapy Coverage Act of 2011” was introduced in June 2011, concurrently in the Senate and the House of Representatives. The introduced bill proposes to amend the current Social Security Act to provide Medicare coverage for home infusion therapy and home infusion drugs.

The summary of the Act is:

• Ensuring timely and appropriate access to home based infusion therapy for Medicare beneficiaries.

• Developing better co-ordination between drug (covered under Medicare part D as Voluntary Prescription Drug Benefit Program) and home infusion therapy services (covered under Medicare part B as Supplemental Security Income (SSI)).

Although the coverage for home based infusion services has been provided by several private insurers as well as several government insurance services (such as state Medicaid programs, Medicare advantage, the Veteran’s administration, Federal Employees Health Benefit plan), the coverage under Medicare has been missing.

The successful passage and implementation of the bill will ensure a significant increased coverage of the patient population of senior citizens (currently covered under Medicare), boosting the home based infusion therapy market potential. The bill if passed will be a substantial opportunity for the market players and can positively impact the market growth rate as well.